Greenpro Capital Corp.

Issuance of 8,500,000 shares on March 31, 2026

On February 13, 2026, the Company entered into a share exchange agreement (the “Share Exchange Agreement”) with Forekast Limited, a company formed under the laws of the British Virgin Islands (“Forekast”) and the shareholders of Forekast listed on Annex A thereto (the “Forekast Shareholders”).

On March 31, 2026 (the “Closing Date”), all conditions for closing were satisfied, and the Company consummated the transactions contemplated by the Share Exchange Agreement. At closing, the Company acquired 1,360 ordinary shares of Forekast from the Forekast Shareholders, representing 13.6% of Forekast’s outstanding equity interests on a fully diluted basis as of the Closing Date. In consideration therefor, the Company issued to the Forekast Shareholders an aggregate of 8,500,000 shares of its common stock, par value $0.0001 (the “Common Stock”), valued at $17,000,000 to the Forekast Shareholders, such shares constituting the “Exchange Shares”. The transaction constituted a minority investment in Forekast and did not result in the Company obtaining control of Forekast.

Set forth below are the details of the Company’s issuance of Common Stock in connection with the minority investment in Forekast described above, as extracted from Annex A to the Share Exchange Agreement during the three months ended March 31, 2026:

As of the date of this report, the Company has total 18,033,123 shares of Common Stock issued and outstanding and the Forekast Shareholders collectively hold approximately 47% of the Company’s Common Stock upon the receipt of 8,500,000 shares of Common Stock from the Company.

Issuance of 800,000 shares on April 16, 2026

On November 18, 2025, the Company entered into an acquisition agreement (the “Acquisition Agreement”) with Lim Chee Yin, an individual (the “Seller”). Pursuant to the Acquisition Agreement, subject to the satisfaction or waiver of the conditions set forth therein, upon consummation of the transaction contemplated in the Acquisition Agreement (the “Closing”), the Company acquired 0.99% of Seller’s shareholdings in Greenophene Technologies Limited, a company incorporated in the British Virgin Islands (“Greenophene”), equivalent to 10 shares of Greenophene (the “Acquisition”).

On April 16, 2026 (the “Closing Date”), all conditions to closing were satisfied, and the Company consummated the transactions contemplated by the Acquisition Agreement. At the Closing, the Company acquired 10 ordinary shares of Greenophene from the Seller, representing a minority interest of 0.99% of Greenophene’s outstanding equity interests as of the Closing Date. In consideration therefor, the Company issued to the Seller 800,000 restricted shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), valued at $1.50 per share, for an aggregate value of $1,200,000 (the “Consideration”).

As of the date of this report, the Company has total 18,033,123 shares of Common Stock issued and outstanding and the Seller holds approximately 4.4% of the Company’s Common Stock upon the receipt of 800,000 shares of Common Stock from the Company.

Issuance of 107,310 shares on April 28, 2026

On April 28, 2026, we entered into a subscription agreement (the “Subscription Agreement”) with our Chief Executive Officer, President and Director, Mr. Lee Chong Kuang, (the “Purchaser”) providing for the private placement of 107,310 shares of Common Stock at a per share purchase price of $2.3297 (the “Offering”) for aggregate gross proceeds of $250,000. The Offering closed on April 28, 2026.